• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Results of the HYSTUB Trial: What Are the Hormonal Consequences of Opportunistic Salpingectomy?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Anti-Müllerian hormone (AMH) is a hormone that reflects ovarian reserve
  • Van Lieshout et al. (Maturitas 2018) assessed whether opportunistic salpingectomy in premenopausal women undergoing hysterectomy has hormonal implications

METHODS:

  • Multicenter randomized controlled trial (RCT)
    • Hysterectomy for Benign Gynaecological Conditions With or Without Tubectomy (HYSTUB) trial
  • Women were randomized to the following
    • Hysterectomy with opportunistic bilateral salpingectomy
    • Standard hysterectomy with preservation of Fallopian tubes
  • Primary outcome: Difference in serum anti-Müllerian hormone concentration (∆AMH)
    • Preop levels vs 6 months postop
  • Secondary outcomes: Surgical outcomes and duration of hospital stay

RESULTS:

  • 104 women were included in the study
    • 52 in each arm of the study
  • Baseline characteristics did not differ between the two groups
  • There was no change in ∆AMH as a result of salpingectomy:
    • -0.14pmol/L in the intervention group and 0.00pmol/L in the control group (p=0.49)
  • Salpingectomy did not impair surgical results nor was their longer hospital stays

CONCLUSION:

  • The addition of salpingectomy to hysterectomy in premenopausal women did not change surgical safety, duration of hospital stay or AMH levels

Learn More – Primary Sources:

Opportunistic salpingectomy in women undergoing hysterectomy: Results from the HYSTUB randomised controlled trial.

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Should Fallopian Tubes Also Be Removed During Ovarian Conserving Benign Hysterectomy? 
Can Anti-Müllerian Hormone Levels Predict Menopause?
‘Opportunistic’ Salpingectomy at the Time of Hysterectomy: Risks vs Benefits
Are There any Minor Risks Involved with the ‘Opportunistic’ Removal of Fallopian Tubes to Prevent Cancer During Hysterectomy or Sterilization Procedures

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site